Latest news

One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are now developing...

Adalvo is delighted to announce the successful EU DCP closure of our Enzalutamide Soft Gel Capsules. We believe to be the first Company to receive an EU approval,  and with this...

The Consortium jointly, through Aztiq II HoldCo, has acquired a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholder in Adalvo. The Consortium’s collective industry experience,...

Adalvo is one of the few companies who can offer a comprehensive diabetes portfolio covering small molecule oral treatments and complex peptide injectables. We understand that diabetes is becoming one of the fast-growing diseases, and...

We are humbled and honored to have been recognized by Global Health and Pharma Magazine's 2022 Global Excellence Awards and have been awarded the title of: Most Innovative B2B Pharmaceutical Company, 2022...

We are proud to announce that our distinguished hybrid / 505(b)(2) asset Gralise® has reached an advanced stage and that Adalvo will move into launch in Q1 2023. With this achievement we add a...

As we strengthen our injection product pipeline, we are pleased to provide a status update on our development of Dalbavancin. The development of this complex niche generic is progressing very...

As we continue to deliver on our brand promise of being the preferred partner and setting a new standard for the future of Pharma, Adalvo provides various solutions and differentiated...

Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked and the submission will be completed in July 2022.

We are pleased to announce that we have now completed our Pivotal BE program for Apremilast Film-Coated Tablets. This product has been developed in collaboration with one of our strategic...

We are pleased to provide a status update on our development of Eribulin injection 0.44mg/ml. The development of this product is progressing very well; our dossier will be available for...

We are pleased to announce that, following the successful completion of our ANDA for Midostaurin Capsules 25mg in the US, we have now completed our Pivotal BE program in Europe....

We are pleased to announce that our US dossier of Semaglutide 1.34mg/ml pre-filled pen is ready and available for licensing in Ex-US markets. We will now move full steam...

Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst...

Aztiq is thrilled to announce the recent establishment of a new entity Arphio a venture initiated in close collaboration with SK Pharma.

Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Apixaban 5mg Film Coated Tablets.

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), a clinical stage company developing innovative stem cell therapies, announced today that the European Commission and the European Medicines...

Adalvo is pleased to announce that we have successfully launched Icatibant in 14 markets. This product is a complex injectable peptide, forming part of our high-value product portfolio offering to...

As this new year begins, Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Vortioxetine Film-Coated Tablets.

Adalvo is thrilled to announce that we have entered into a strategic collaboration deal with Naari Pharma, a vertically integrated women’s health pharmaceutical business, based in Bangalore, India.

Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on...